Valbiotis SA (DE:8JD)
FRANKFURT:8JD
8JD Stock Chart & Stats
€0.67
-€0.01(-0.67%)
At close: 4:00 PM EST
€0.67
-€0.01(-0.67%)
Day’s Range― - ―
52-Week Range€0.53 - €1.29
Previous CloseN/A
Volume0.00
Average Volume (3M)407.00
Market Cap
€23.88M
Enterprise Value€20.26M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding23,698,235
10 Day Avg. Volume1,223
30 Day Avg. Volume407
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€4.53M
Bulls Say, Bears Say
Bulls Say
Preventive Nutrition FocusValbiotis’ focus on clinically substantiated preventive nutrition targets large, structural markets (metabolic and cardiovascular health). Clinical positioning supports sustained demand, institutional partnerships and recurring sales opportunities versus one-off products over the medium term.
Clinical And Formulation Know-howOwning clinical evaluation capabilities and formulation expertise creates durable barriers to entry for differentiated supplements. This know-how supports reproducible product development, credibility with healthcare partners and higher conversion in regulated or evidence-driven channels.
Manageable LeverageReported leverage appears moderate versus highly leveraged peers, providing some balance-sheet flexibility. While equity has declined, current debt levels are not extreme, enabling breathing room to seek financing or execute commercialization without immediate solvency distress.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows the business is not self-funding and depends on external capital. Continued cash burn limits runway, increases dilution risk, and constrains investments in commercialization or R&D over the medium term without new funding.
Consistent Losses And Weak MarginsPersistent negative operating and net margins indicate structural inability to cover operating costs at current scale. This reduces reinvestment capacity, heightens financing needs, and makes it harder to reach breakeven absent material revenue scale or cost restructuring.
Negative Gross Profit And Revenue VolatilityNegative gross profit signals that current pricing or cost base cannot absorb fixed/variable costs at present volumes. Paired with volatile revenue, this undermines forecasting and execution, increasing the probability that short-term revenue gains will not sustainably improve profitability.
Valbiotis SA News
8JD FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.53 and its highest was €1.29 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €23.88M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 180 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 23,698,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.309%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in DE:8JD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Technical Analysis
Nicox SA
―
GenSight Biologics SA
―
Advicenne SA
―
NFL Biosciences SA
―
Plant Advanced Technologies SA
―